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Summary
 
The 
 
Trypanosoma cruzi
 
 
 
trans
 
-sialidase can sensitize mice to become highly susceptible to 
 
T. cruzi
 
invasion, through mechanisms that remain unknown. In pursuing this observation, we found
that purified 
 
trans
 
-sialidase induces the selective release of biologically active interleukin (IL)-6
in naive human intestinal microvascular endothelial cells (HIMECs), peripheral blood mono-
nuclear cells (PBMCs), and bladder carcinoma cells. The 
 
trans
 
-sialidase action was independent
of its catalytic activity, as demonstrated with a genetically engineered 
 
trans
 
-sialidase mutant, an
enzymatically active polypeptide, and cocultures of PBMCs with epimastigotes and trypomas-
tigotes. Instead, the 
 
trans
 
-sialidase action was reproduced with a recombinant COOH-terminal
tandem repeat and with synthetic peptides modeled on the tandem repeat. Most interesting,
HIMECs infected with a trypomastigote population expressing 
 
trans
 
-sialidase effectively re-
leased IL-6, but did not upon infection with the counterpart trypomastigote population ex-
pressing low 
 
trans
 
-sialidase levels. IL-6 is a key factor in the regulation and symptom formation
of infection caused by several types of viruses, such as HIV and influenza A virus. However, the
function of IL-6 in protozoan and other parasitic diseases remains unclear. The unique findings
presented here suggest that 
 
trans
 
-sialidase is a major inducer of IL-6 secretion in 
 
T
 
.
 
 cruzi
 
 infec-
tion, independently of immune cell activation. Such IL-6 secretion might underlie some fea-
tures of Chagas’s disease, such as pyrexia, neuroprotection, and fibrosis, and might result in the
undermining of normal acquired immunity against 
 
T
 
.
 
 cruzi
 
.
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T
 
he protozoan 
 
Trypanosoma cruzi
 
 causes Chagas’s disease,
a chronic debilitating condition afflicting millions of
people in this Hemisphere. 
 
T
 
.
 
 cruzi
 
 invasion results in the
production of several cytokines, some of which, like IL-6,
can be released independently of antigenic stimulation of B
and T lymphocytes. This is the case in the in vitro
 
 
 
infection
of human umbilical vein endothelial cells (HUVECs),
 
1
 
 where
 
T
 
.
 
 cruzi
 
 upregulates the gene for IL-6 and other cytokines (1).
Likewise, coculture of normal human PBMCs with 
 
T
 
.
 
 cruzi
 
results in the proliferation of lymphocytes and the production
of cytokines including IL-6 (2). In vivo,
 
 
 
IL-6 is found to be
consistently elevated in the sera of animals experimentally in-
fected with 
 
T
 
.
 
 cruzi 
 
(3) and in humans with acute Chagas’s
disease (1). Inflamed heart, aorta, and spleen of chagasic ani-
mals, as well as the chronic chagasic heart of humans, are en-
riched in IL-6–producing cells, particularly endothelial cells
and mononuclear cells (4–7). These results suggest that IL-6 is
upregulated in Chagas’s disease not only by immune but also
by nonimmune mechanisms. However, the molecular basis
for the IL-6 upregulation in 
 
T
 
.
 
 cruzi 
 
infection is unknown.
IL-6 is a multifunctional cytokine that regulates the infec-
tion of several types of viruses. For example, normal PBMCs
exposed to HIV enhance production of IL-6 (8). In addition,
the majority of HIV-infected individuals exhibit elevated
serum levels of IL-6 (9). IL-6 seems to have an autocrine
effect on HIV replication, because blocking IL-6 produc-
tion dramatically reduced viral titers (10). HIV upregulates
expression of IL-6 through the viral transactivating Tat,
which interacts with IL-6 promoter to increase IL-6 tran-
 
1
 
Abbreviations used in this paper:
 
 CD, catalytic domain of TS; CM, condi-
tioned medium; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
HIMEC, human intestinal microvascular endothelial cell; HUVEC, hu-
man umbilical vein endothelial cell; NTA, nitrilotriacetic acid; PN-1,
penetrin; RANTES, regulated upon activation, T cell expressed and se-
creted; TS, 
 
trans
 
-sialidase; TR, tandem repeat; TS/CM, TS-stimulated
CM; VCNA, 
 
Vibrio cholera
 
 neuraminidase. 
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scription (11). These findings suggest an important role for
IL-6 in maintaining HIV infection. Influenza provides an-
other example of a direct relationship between viral infec-
tion and IL-6 production. As with HIV, exposure of nor-
mal human PBMCs to human influenza A virus results in
the production of IL-6 and other cytokines (12). Further-
more, IL-6 levels in nasal lavage fluids and in the circulation
of human volunteers infected with influenza A virus corre-
lated directly with viral titers, temperature, mucus produc-
tion, and symptom score (13). These results implicate IL-6
as an important mechanism both in symptom formation
and in host defense in influenza. IL-6 is also implicated in
rhinovirus infection (14).
However, not much is known about the function of IL-6
in infections produced by parasites, including 
 
T
 
.
 
 cruzi
 
 (15, 16).
Ascertaining the role IL-6 plays in Chagas’s disease would be
facilitated if it was known what in 
 
T
 
.
 
 cruzi
 
 induces IL-6 pro-
duction in normal cells before the development of acquired
immunity, as this might give clues to how the parasite at-
tempts to subvert immune regulation or how the host seeks to
eliminate parasitism. The results presented here identify for the
first time a 
 
T
 
.
 
 cruzi
 
 glycoprotein with 
 
trans
 
-sialidase (TS) activ-
ity capable of selectively upregulating IL-6 secretion in naive
human cells independently of antigenic stimulation.
TS was originally discovered by its ability to catalyze the
release of sialic acid from glycoconjugates in solution or on
cell surfaces (i.e., neuraminidase or sialidase activity [17]).
Subsequently, it was demonstrated that TS could transfer
sialic acid to 
 
b
 
-galactosyl acceptors (sialyl transferase activ-
ity [18–20; for a review, see reference 21]). TS is attached
to the trypomastigote outer membrane through a glyco-
sylphosphatidylinositol anchor (22, 23) and is present as a
soluble factor in the extracellular milieu in the bloodstream
of 
 
T
 
.
 
 cruzi
 
–infected mice (17) and humans (24). Therefore,
the 
 
T
 
.
 
 cruzi
 
 neuraminidase is strategically located for a role
in mediating trypanosome–host interactions, such as by al-
tering immune functions.
A few years ago, we found that mice sensitized with TS in
their footpads became highly susceptible to trypanosomal in-
fection compared with mice sensitized with control medium,
bacterial neuraminidase, or LPS (25). The dosage (low nano-
grams per mouse) and kinetics (1–2 h before parasite inocula-
tion) of TS sensitization suggested that the enzyme enhanced
virulence by altering the dynamics of innate and/or acquired
immune responses to 
 
T
 
.
 
 cruzi
 
, independent of antigenic stim-
ulation of B and T cell receptors. This could be accomplished
if TS were to activate cytokine receptor signaling pathways
by binding either directly to cytokine receptors or to other
surface receptors whose activation would lead to cytokine se-
cretion. If so, the TS-dependent cytokines could, in turn,
subvert normal anti–
 
T
 
.
 
 cruzi
 
 immune responses.
To begin to test this hypothesis, we screened for cyto-
kines in media conditioned by TS stimulation of various hu-
man cells relevant to the pathogenesis of Chagas’s disease.
We found that intact TS and recombinant and synthetic
fragments of TS selectively stimulated secretion of biologi-
cally active IL-6 in primary cultures of human intestinal
microvascular endothelial cells (HIMECs) and in normal
 
PBMCs. Surprisingly, the secretagogue action of TS relied
on its COOH-terminal tandem repeat (TR) and not on its
catalytic domain (CD). These findings raise the possibility
that TS plays a role in 
 
T
 
.
 
 cruzi
 
 invasion and in the pathol-
ogy of Chagas’s disease, at least in part, by upregulating IL-6
secretion in naive cells.
 
Materials and Methods
 
Cell Culture.
 
Dr. Claudio Fiocchi (Case Western Reserve
University School of Medicine, Cleveland, OH) provided pri-
mary cultures of HIMECs isolated from normal jejunal mucosa/
submucosal tissue (26). They were cultured in fibronectin-coated
plasticware in MCDB medium (Sigma Chemical Co.) supple-
mented with 20% fetal bovine serum, 90 
 
m
 
g/ml heparin, and 50
 
m
 
g/ml of endothelial cell growth factor (Sigma Chemical Co.).
T-24 cells (CRL-1998; American Type Culture Collection) were
cultured in M199 medium supplemented with 10% fetal bovine
serum. PBMCs were purified by Ficoll-Paque gradient as de-
scribed (27). Vero cells were grown in RPMI medium with 5%
Nu serum and infected with the Silvio X-10/4 strain of 
 
T. cruzi
 
as described previously (25). Epimastigotes were grown as described
previously (17, 23).
 
Purification of Native TS and Related Proteins.
 
TS was purified
by immunoaffinity chromatography as described previously (20).
In brief, supernatants from 
 
T. cruzi
 
–infected Vero cells were
passed on a protein G–Sepharose (Amersham Pharmacia Biotech)
column adsorbed with mAb TCN-2 specific for the LTR do-
main of TS. Bound TS was eluted with TR1 peptide (DSSAH-
GTPSTPA) in the presence of 0.1% octyl glucopyranoside. TS
was concentrated by ultrafiltration in Amicon-10 and washed ex-
tensively with PBS, pH 7.8, to remove the TR peptide. The
neuraminidase from 
 
Vibrio cholera
 
 (VCNA) was purchased from Cal-
biochem. Penetrin (PN-1) was isolated by heparin affinity chroma-
tography as described previously (28). All reagents, glassware, and
plasticware used in the isolation of the various proteins were LPS
free. To eliminate residual LPS, the purified materials were passed
through two distinct resins that remove endotoxin by different
mechanisms, END-X B15 (Associates of Cape Cod, Woods Hole,
MA) and AffinityPack™ Detoxi-Gel™ (Pierce Chemical Co.), fol-
lowing the recommendations of the manufacturers.
 
Cloning and Expression of Catalytic and LTR Domains of TS.
 
The
DNA fragment corresponding to the CD was amplified by PCR on
DNA template from TS clone 19Y of the Silvio strain of 
 
T
 
. 
 
cruzi
 
trypomastigotes (22). The primers for CD were 5
 
9
 
-GGAATTC-
CATATGGCACCCGGATCGAGCCGAGTT-3
 
9 
 
and 5
 
9
 
-CCG-
CTCGAGGCTCAAGAACAAGGTCCTGATCG-3
 
9
 
. The am-
plified fragment was cloned into pET-23b (Novagen) with a stretch
of six His residues at the COOH terminus of the expressed pro-
teins. For protein production, plasmids were used to transform the
BL21 DE3 bacterial strain (Novagen) containing a chromosomal
copy of the T7 RNA polymerase gene. Expression was induced
by isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside (IPTG). To isolate the
recombinant CD fragment, bacterial lysates were prepared by os-
motic shock in 40 mM phosphate buffer, pH 7.5, 0.3 M NaCl,
1% Triton X-100, 1 mM PMSF, followed by brief sonication.
The CD peptide was purified on a Ni
 
2
 
1
 
-nitrilotriacetic acid (NTA)/
agarose column as recommended by the manufacturer (Novagen).
CD was further purified by FPLC on the anion-exchange col-
umn Mono-Q HR (Amersham Pharmacia Biotech), as described
previously (20, 25). All reagents were LPS free and passed
through the END-X B15 resin to remove residual LPS. 
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The full-length COOH-terminal LTR (LTR fragment) of Sil-
vio TS, clone 7F (22), was isolated as follows: LTR, subcloned from
a pMelBac plasmid (Invitrogen) containing the TS gene, was di-
gested with PvuII-SalI and ligated into EcoRV-SalI sites of pET-
20b (Novagen). The LTR DNA was introduced into the NcoI-
HindIII sites of pFASTBAC HTb vector (GIBCO BRL). The
Bac-to-Bac system (GIBCO BRL) was used to generate recom-
binant baculovirus, which in turn was used to infect Sf 9 cells.
Recombinant LTR protein was purified by Ni
 
2
 
1
 
-NTA column
(Novagen) affinity chromatography. The LTR fragment thus
generated contains the full-length TR of clone 7F with 44 re-
peats plus TS sequences of 26 and 40 amino acids upstream and
downstream of the repeat, respectively. Purified LTR was passed
through AffinityPack™ Detoxi-Gel™ to remove residual LPS.
 
Preparation of TS-154 and TS-H32 Constructs.
 
Construct TS-154
is derived from enzymatically active 
 
trans
 
-sialidase clone 154 of
the Y strain of 
 
T
 
.
 
 cruzi
 
 (29). The NH
 
2
 
 terminus of clone 154 was
amplified by PCR using primers NU-17 (27 mer, 5
 
9
 
-GCCCAT-
GGCACCCGATCGAGCCGAGTT-3
 
9
 
) and NU-18 (20 mer,
5
 
9
 
-CGGAATTTTCATCACCAATG-3
 
9
 
) with restriction sites
shown in Fig. 4 A. NU-17 was designed to introduce starting
ATG codon just before the NH
 
2
 
 terminus of mature TS protein,
and a NcoI site for subcloning. The PCR product of NU-17 and
NU-18 was treated with NcoI and BglII, and subcloned into the
NcoI and BamHI sites of pET-21d (Novagen). Most of the 12
amino acid repeats and hydrophobic region at the COOH ter-
minus were removed by PCR using primers NU-19 (24 mer,
5
 
9
 
-GTTCCGAACGGTTTGAAGTTTGCG-3
 
9
 
) and NU-20 (25
mer, 5
 
9
 
-CTGTCGACGGGAGTTGAGGGCGTAC-3
 
9
 
). NU-20
corresponds to the partial sequence of the TR and, in addition,
contains a SalI site. The PCR product with the minimum numbers
of repeats (i.e., five repeats) was selected and used to replace the
original COOH terminus of clone 154 at unique MluI site (see
Fig. 4 A). The DNA fragment with unique BamHI-SalI sites was
ligated to the pET-21d plasmid containing the NH
 
2
 
-terminal re-
gion of TS using the BamHI and XhoI sites of the vector, to yield
construct TS-154 (see Fig. 4 A). To generate construct TS-H32,
the BglII-PstI DNA fragment of pTS-154 was replaced with the
corresponding fragment from the gene 121 (29). The 
 
trans
 
-siali-
dase gene 121 is catalytically inactive due to a single amino acid
difference in the BglII-PstI fragment, with histidine (H374) re-
placing tyrosine in the catalytically active TS gene 154 (29). Thus,
construct TS-H32 should be enzymatically inactive, as deter-
mined experimentally (see Fig. 4 B). All constructs were verified
by automated sequencing (ABI Perkin Elmer) using BigDye ter-
minator. Production and purification of TS-154 and TS-H32
proteins were identical to the method described above for the
CD construct.
 
Immunoassays for Cytokines.
 
Endothelial cells and T-24 cells
were plated on 24-well plates at a density of 10
 
5
 
 cells/well, while
PBMCs were plated in the similar wells at 10
 
6
 
/well. Cells were
incubated with the various test reagents at the concentrations and
for the time indicated in the figures in triplicate points. Poly-
myxin B was used at 10 
 
m
 
g/ml in all cell cultures, as it did not af-
fect any parameter tested. Cytokines and chemokines released in
the culture supernatants were measured by ELISA assay following
the instructions of the manufacturer (Endogen). The cytokines
tested were IL-1
 
b
 
, IL-4, IL-6, IL-8, IL-10, IL-12, IFN-
 
g
 
, and
TNF-
 
a
 
, and the chemokines were RANTES (regulated upon
activation, normal T cell expressed and secreted) and monocyte
chemotactic protein 1 (MCP-1). Negative control were cells in-
cubated in medium containing polymyxin B at 10 
 
m
 
g/ml, and
positive control always included cells incubated with bacterial LPS
 
at the low nanogram per milliliter range (for PBMCs or HIMECs)
or in the microgram per milliliter
 
 
 
range for carcinoma T-24 cells.
In some experiments, IL-1
 
b
 
 or TNF-
 
a
 
 was used as positive con-
trol for cytokine release. Bioassay for IL-6 was performed using
IL-6–dependent human DS-1 cells (30). In brief, 10
 
4
 
 cells/well
were plated in 96-well plates and incubated for 24 h in IL-6–free
medium (10% FCS in RPMI) containing several dilutions of TS-
conditioned medium (TS/CM) or exogenous rIL-6, pulsed for
4 h with 0.5 mCi [3H]thymidine, and harvested to determine ra-
dioactivity incorporation in a microplate scintillation instrument
(Packard). In some experiments, a neutralizing IL-6 rabbit IgG or
normal rabbit IgG (Endogen) was added to the dilutions of TS/
CM before assaying for growth stimulation of DS-1 cells. Condi-
tioned media were prepared by incubating PBMCs or T-24 cells
for 24 h in 10% FCS/RPMI without (CM) or with (TS/CM) TS
at 1 mg/ml. Supernatants were centrifuged at 1,000 g to remove cell
debris and were kept frozen at –208C until use.
PCR of Reverse-transcribed mRNA. Semiquantitative analysis of
cytokine mRNA was performed by the primer-dropping method
(31). RNA of endothelial cells (105) or PBMCs (106) that had
been or not stimulated with TS at 1 mg/ml for 24 h, was purified
by acid guanidinium isothiocyanate-phenol-chloroform-TRI re-
agent (Molecular Research Center). 2 mg of total RNA was con-
verted to cDNA in a volume of 20 ml using random hexamer
primers according to the manufacturer’s instructions (GIBCO
BRL). Primers for human IL-6 were 59-ATGAACTCCTTCT-
CCACAAGCGC and 59-GAAGAGCCCTCAGGCTGGACTG,
and for glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
59-CGGAGTCAACGGATTTGGTCGTAT and 59-AGCCTT-
CTCCATGGTGGTGAAGAC. The PCR mixture contained
20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl2, 1 mM
dNTP, 200 pM primers, and 1 U of Taq polymerase in 50 ml.
Thermal cycling conditions were: denaturation step, 958C for 5 min;
35 cycles of 958C for 30 s, 608C for 30 s, and 758C for 1 min, and
a final step of 758C for 5 min. At cycle 9, GAPDH primers were
added. 5 ml of the PCR product was analyzed through 2% agarose
gel electrophoresis in the presence of 1 mg/ml ethidium bromide.
Cocultures of Epimastigotes and Trypomastigotes with PBMCs.
Normal human PBMCs (106/well) were coincubated in 10% FCS/
RPMI with either epimastigotes or trypomastigotes (105/well for
each stage) for 48 h at 378C. IL-6 was measured by ELISA in cell-
free supernatants (obtained by centrifugation of the cultures at
2,500 g for 5 min) at various times after the start of the cocultures. TS
activity in the parasites was obtained before the start of the cultures.
Kinetics of IL-6 Production by HIMECs Incubated with TS1 and
TS2 Populations and with Leishmania major. T. cruzi trypomastigotes
expressing TS on their surface (TS1 parasites) or expressing low or
no TS (TS2 parasites) were purified by magnetic beads coated with
the mAb TCN-2, as described previously (32). HIMECs, plated
(5 3 104/well) on 24-well plates for 24 h, were infected with 106
trypomastigotes (unfractionated, TS1, or TS2) or with L. major
promastigotes, strain V1 (gift from Dr. Stephen Beverley, Wash-
ington University, St. Louis, MO). At various times after infection,
aliquots of the supernatants were collected, centrifuged at 1,000 g,
filtered in 0.22 mm nitrocellulose, and assayed for IL-6 by ELISA.
LTR Depletion. 200 ml of protein G–Sepharose (Amersham
Pharmacia Biotech) was adsorbed with culture supernatants of the
mAb TCN (IgG1 isotype) or of a control mAb IgG1 specific for
p-azo-phenylarsonate (provided by Dr. Thereza Imanishi-Kari,
Tufts University School of Medicine), and washed with 20 vol of
LPS-free PBS, pH 7.2. 3 mg of LTR was loaded to either protein
G/TCN-2 or protein G/control IgG1 column; the effluent was
reapplied five times to the respective column. The last flow-1828 The Trypanosoma cruzi Neuraminidase Stimulates IL-6 Secretion
through of each column was collected in 200 ml in a separate
LPS-free tube, and the columns were washed with five column
volumes of PBS. Elution of bound LTR was by mixing the resins
with a spatula, followed by centrifugation at 250 g for 5 min at
48C. Effluents and eluates were constituted to the original vol-
ume and added to T-24 cells. After 24 h, IL-6 in the T-24 cell
supernatants was determined by ELISA.
IL-6 Production by PBMCs Stimulated with TR Peptides. TR pep-
tides (see Table I) were synthesized at the Tufts University Syn-
thesis Facility. Each peptide was purified by HPLC, and the num-
ber of amino acids and molecular weight of each peptide were
verified by mass spectrography. Peptides were dissolved in growth
medium (10% FCS in RPMI) and added at various concentra-
tions to 106 PBMCs/well in 24-well plates. After 24 h, IL-6 was
assayed by ELISA in the conditioned supernatants.
Results
TS Promotes IL-6 Secretion in Normal HIMECs, PBMCs,
and in Cancer Cells. Endothelial cells mediate tissue inflam-
mation, in part, through the secretion of proinflammatory
cytokines and the selective expression of adhesion molecules
in the vascular bed (33). Most studies with endothelial cells
rely on HUVECs, as they are readily available and easy to
isolate. However, the majority of physiological and patho-
logical events mediated by endothelial cells, in particular in-
flammation, wound healing, and leukocyte homing through
postcapillary venules, occur at the level of microcirculation
(34). Furthermore, endothelial cell populations vary from or-
gan to organ and in different vessels within an organ (35).
Most important, the pattern of cytokine secretion and prolif-
eration of a microvascular endothelial cell, HIMEC, differed
from that of HUVECs in response to various stimuli (36,
37). Thus, due to the relevance of the intestinal microvascu-
lar endothelium to the pathogenesis of the megacolon in
Chagas’s disease, and the possibility that TS subverts host im-
mune responses by directly reacting with nonimmune cells,
we attempted to determine whether HIMECs isolated from
normal human mucosa would secrete cytokines in response
to TS stimulation.
For this purpose, we incubated HIMEC monolayers with
various concentrations of purified TS for 24 h and measured
the concentration of eight cytokines (IL-1b, IL-4, IL-6, IL-8,
IL-10, IL-12, IFN-g, and TNF-a) and two chemokines
(RANTES and monocyte chemotactic protein 1 [MCP-1])
in the conditioned HIMEC supernatants. We found the con-
centration of IL-6 to be elevated in the conditioned superna-
tants in a manner dependent on the TS input (Fig. 1 A). In
contrast, the concentration of the other cytokines did not
increase in response to TS stimulation under conditions in
which bacterial LPS at 50 ng/ml released IL-1b, IL-8, and
TNF-a (data not shown). Similar IL-6 upregulation was
observed with two other primary cultures of HIMECs (data
not shown). The IL-6 concentration produced by HIMECs in
response to 1 mg/ml of TS corresponded to that induced by
50 ng/ml of a bacterial LPS (data not shown). Thus, HIMECs
appear to be much more sensitive to produce IL-6 in re-
sponse to bacterial LPS than to TS. A control VCNA cor-
responding to the neuraminidase activity of TS did not
stimulate detectable IL-6 secretion in HIMECs (Fig. 1 A),
suggesting that the TS action did not depend on its intrinsic
Figure 1. Dose–response (A–C) and time course (D and
E) of IL-6 release by normal human cells and cancer cells.
HIMECs (A), PBMCs (B), and T-24 carcinoma cells (C)
were incubated with the indicated concentrations of TS,
VCNA, and PN-1, and after 24 h, the conditioned super-
natants were analyzed for their content of IL-6 and other
cytokines by ELISA. HIMECs (D) and PBMCs (E) were
incubated with 1 mg/ml TS or 1 mU/ml VCNA for the
times indicated. The VCNA units correspond to the
neuraminidase activity of TS. Results similar to those in A,
B, and C were repeated 10, 9, and 10 times, respectively.1829 Saavedra et al.
glycosidase activity. Another control protein, the T. cruzi
heparin-binding penetrin (PN-1) thought to promote para-
site invasion (28), was not effective in stimulating IL-6 se-
cretion (Fig. 1 A), further emphasizing the selectivity of the
TS action.
TS also stimulated IL-6 release in normal PBMCs (Fig. 1 B),
another class of human cells relevant to the immunity against
T. cruzi. The result in Fig. 1 B is for one blood donor, but
a similar result was obtained with three other blood donors
(data not shown). In addition, TS stimulated IL-6 secretion
in the human bladder carcinoma T-24 cell line (Fig. 1 C).
Previous work has shown that T-24 cells express IL-6 con-
stitutively and in response to cytokine stimuli (38, 39). TS-
induced IL-6 secretion in the T-24 bladder carcinoma cells
further underscores the neuraminidase action for nonim-
mune cells. Interestingly, the IL-6 output resulting from the
24-h stimulation of T-24 carcinoma cells with 1 mg/ml of
TS corresponded to that induced by 0.75 mg/ml of bacte-
rial LPS under the same conditions (data not shown). Thus,
in this cancer cell line, TS was nearly as good as bacterial
LPS in stimulating IL-6 secretion.
IL-6 is produced by a large variety of cells, including en-
dothelial cells, monocytes, fibroblasts, keratinocytes, T cells,
mast cells, neutrophils, tumor cell lines, and cells of neural
origin (40). Although we found that TS stimulates IL-6
production in endothelial cells and PBMCs, it is likely that
the neuraminidase will also stimulate IL-6 release in other
cell types. However, normal human neutrophils, which are
capable of secreting IL-6 in response to various stimuli such
as TNF-a and GM-CSF (41), did not produce detectable
IL-6 when stimulated with TS under conditions in which
TNF-a did (data not shown). Thus, not every human cell
type may secrete IL-6 upon stimulation with TS.
Kinetics of TS-dependent IL-6 Secretion. The kinetics of
TS-induced IL-6 secretion revealed maximum effect after
24 h stimulation in both HIMECs and PBMCs (Fig. 1, D and
E). This response followed the upregulation of IL-6 tran-
scripts, which was maximal 4–10 h after TS stimulation
(Fig. 2). These results suggest that TS triggers synthesis and
then secretion of IL-6, consistent with the effect of conven-
tional cytokine agonists in the same cell types (37, 38).
TS-conditioned Cell Supernatants Restore Growth of an IL-6–
dependent B Lymphoma Cell Line. The DS-1 B lymphoma
cells have an intact IL-6 receptor signaling pathway, but
because they cannot produce IL-6, the cells will die unless
exogenous human IL-6 is added to the culture medium
(30). Therefore, this cell line is a useful probe for the bio-
logical assay of human IL-6.
To determine whether TS induces secretion of biologi-
cally active IL-6, we measured the ability of conditioned
media to promote growth of DS-1 cells. We prepared con-
ditioned media by incubating PBMCs or T-24 cells for 24 h
in 10% FCS/RPMI without (CM) or with (TS/CM) TS at
1 mg/ml. We found that TS/CM, but not CM, restored
growth of the DS-1 lymphoma cells in a dose-dependent
manner, and that a neutralizing IL-6 antibody suppressed
the growth-promoting activity of TS/CM (Fig. 3). These
results indicate that TS-dependent IL-6 released by PB-
MCs and T-24 cells is biologically active. In addition, we
also conclude that the T. cruzi neuraminidase is not an IL-6
agonist because it did not restore growth of the DS-1 cells
when the enzyme was added to normal growth medium
lacking exogenous IL-6 (Fig. 3).
TS Mediates IL-6 Release in Nonimmune Cells through Its
COOH-terminal TR, but Not Through Its CD. To begin to
dissect structural features of TS that elicit IL-6 release in
normal human cells, we first determined whether the cata-
lytic activity of TS mediates IL-6 secretion in immunologi-
cally naive human cells. For this, we compared the action
of the catalytically inactive TS mutant TS-H32 with that of
catalytically active TS-154 protein. Both TS-154 and TS-
H32 constructs derive from the Y strain of T. cruzi (29),
whereas the TS used in the experiments displayed in Figs.
1–4 was derived from the Silvio strain (22). Both TS-H32
Figure 2. Semiquantitative determination of PCR-amplified IL-6
mRNA in resting and TS-activated PBMCs. Representation of amplified
IL-6 and GAPDH mRNA after stimulation with TS at 1 mg/ml for the
times indicated. Top, agarose gel; bottom, densitometric measurement.
Experiments repeated three times with similar results.
Figure 3. TS/CM restores
growth of IL-6–dependent DS-1
B lymphoma cells. PBMCs and
T-24 cells were incubated with-
out (CM) or with (TS/CM) TS
for 24 h, and the resulting condi-
tioned media were used at the
indicated dilutions to supplement
IL-6–free medium for DS-1 cells.
A neutralizing IL-6 rabbit IgG at
1 mg/ml was added to each dilu-
tion of the TS/CM (TS/CM 1
IL-6 Ab). Normal rabbit IgG had
no effect on the growth-promot-
ing action of TS/CM (data not
shown). TS was added directly
to the IL-6–free growth me-
dium at 1 mg/ml, which corre-
sponds to 1:5 dilution shown on
the x-axis. The plot above is for TS-CM from PBMC cultures, but similar
results were obtained with T-24 cultures. Experiment repeated twice with
similar results.1830 The Trypanosoma cruzi Neuraminidase Stimulates IL-6 Secretion
and TS-154 constructs contain five TR units (Fig. 4 A).
Although TS-H32 differs from TS-154 in six amino acid
substitutions in the CD (Fig. 4 A), the difference in enzy-
matic activity between the two constructs is attributed to a
single amino acid, with tyrosine (Y374) in the active gene
(TS-154) changed to histidine in the inactive gene (TS-
H32) (Fig. 4, A and B). To our surprise, enzymatically ac-
tive TS-154 was as powerful as enzymatically inactive TS-
H32 in stimulating IL-6 secretion in PBMCs (Fig. 4 C) and
T-24 cells (data not shown).
The results with the TS-154 and TS-H32 constructs
suggest that the catalytic activity of TS does not mediate
IL-6 release in naive cells. This was confirmed with the use
of recombinant CD of TS. The NH2-terminal domain of
TS is 663 amino acids long and contains the enzymatically
active CD (Fig. 4 A). In contrast, the enzymatically inactive
COOH-terminal domain is made up of a 12 amino acid
unit repeated 44 times in the 7F clone of TS derived from
the Silvio strain of T. cruzi (LTR) (22; and data not shown).
Recombinant His-tagged CD was purified from Escherichia
coli lysates by binding to and elution from Ni21-NTA/agarose
column and by ion-exchange chromatography on Mono-Q
columns (FPLC; see Materials and Methods). Recombi-
nant His-tagged LTR was isolated from insect cell lysates
by immunoaffinity to the mAb TCN-2 and to Ni21-agarose
columns (see Materials and Methods).
Addition of CD to T-24 cells did not promote IL-6 release,
whereas addition of LTR effectively released IL-6 in a dose-
dependent manner (Fig. 5 A). Similar results were obtained
in the IL-6 release by PBMCs, in which LTR, but not CD,
upregulated IL-6 release (data not shown). To confirm that
LTR is a mediator of IL-6 release, we depleted LTR from
solution in a protein G–Sepharose column adsorbed with
TCN-2. TCN-2 is an IgG1 mAb specific for LTR routinely
used in our lab to purify TS (20). The flow-through of such
TCN-2 affinity column, which was devoid of LTR poly-
peptide, as determined by immunoblot analysis (data not
shown), did not stimulate IL-6 release in T-24 cells (Fig. 5 B).
In contrast, the flow-through of a control IgG1 column con-
tained LTR polypeptide and stimulated IL-6 secretion (Fig.
Figure 4. The catalytic activity of TS does not mediate IL-6 release in
PBMCs and T-24 cells. Diagram of TS (Silvio strain, clone 7F; see refer-
ence 22) and of TS-154 and TS-H32 constructs (derived from Y strain,
clones 154 and 121, respectively; see reference 29). NU-17, -18, -19, and
-20 refer to primers used to make the constructs (see Materials and Meth-
ods). H6 refers to the 6xHis tag. Insert shows the sequence comparison
between TS-154 and TS-H32 in the BglII-PstI fragment of TS. The se-
quence of TS-H32 is identical to the sequence of TS-154 except where
indicated with the amino acid letter code. (B) Catalytic activity for each
TS construct. (C) IL-6 secretory activity of TS and its respective deriva-
tives for PBMCs. Similar results were obtained with T-24 cells.
Figure 5. TS stimulates IL-6 release in T-24 cells via its TR. (A) Dose–
response. T-24 cells were stimulated for 24 h with the indicated concen-
trations of recombinant LTR or CD domains of TS. IL-6 in the condi-
tioned supernatants was assayed by ELISA. Similar results were obtained
with PBMCs. (B) Immunodepletion of LTR. An LTR solution was
passed through a protein G–Sepharose column adsorbed with either anti-
LTR mAb TCN-2 (TCN-2) or control anti–p-azo-phenylarsonate IgG1
(Ctrl/IgG1). The flow-through of both columns was added to T-24 cells
for 24 h, and the resulting conditioned media were assayed for IL-6 by
ELISA. Eluate for each column was obtained by mechanical stirring of
the agarose followed by centrifugation. Eluates were tested for IL-6–
secretory activity in the same way as the flow-through.1831 Saavedra et al.
5 B). Furthermore, elution of LTR from the TCN-2/protein
G column restored the IL-6–secretory power of the original
preparation, whereas similar elution from the IgG1 control
column did not (Fig. 5 B). Therefore, these results establish
LTR as mediator of IL-6 secretion in naive human cells.
Epimastigotes, Whose TS Lacks LTR, Do Not Efficiently In-
duce IL-6 Secretion in Normal PBMCs. Epimastigote, a non-
invasive stage of T. cruzi, expresses TS with the same carbo-
hydrate specificity as the trypomastigote enzyme (17, 42;
Fig. 6 A). Yet, coculture of normal PBMCs with live epi-
mastigotes did not result in IL-6 secretion under conditions
in which coculture with trypomastigotes did (Fig. 6 B). This
is not a paradox, because the TS of epimastigote, with a CD
84% identical to the counterpart TS of trypomastigotes
(42), lacks LTR, as determined by immunoblot analysis with
LTR-specific mAb (23, 42) and by gene cloning (43). There-
fore, the failure of live epimastigotes to release IL-6 from
PBMCs supports the conclusion that LTR, and not CD, is
the active TS domain upregulating IL-6 in normal human
cells. In addition, it emphasizes the selectivity of trypomasti-
gote TS in stimulating cytokine secretion in normal cells.
Synthetic Peptides Based on Silvio LTR Reproduce the Secreta-
gogue Action of Intact TS. Given that LTR is the domain that
mediates for IL-6 secretion, and that the LTR of TS-154 and
TS-H32 contains only five COOH-terminal repeats (Fig. 4
A), one would expect that LTR-based synthetic peptides up
to five units should stimulate IL-6 secretion in human cells.
To test the above hypothesis, we prepared synthetic pep-
tides TR1, TR2, TR3, TR4, and TR5, which correspond
to the 12, 24, 36, 48, and 60 amino acid sequence proximal
to the COOH terminus of the catalytic domain of Silvio TS
(22; Table I). We then tested whether these synthetic pep-
tides could stimulate IL-6 release in PBMCs. We found that
TR4 and TR5 peptides were active in promoting IL-6 re-
lease, whereas TR1, TR2, and TR3 were less active (Fig. 7).
The results with TR peptides confirm that the TR is the TS
moiety that mediates IL-6 release in naive human cells.
HIMECs Strongly Induce IL-6 Secretion When Infected with
a Trypomastigote Population Bearing a TS1, but Not a TS2
Phenotype. Extracellular trypomastigotes can be subdivided
into two populations based on the relative abundance of
TS (32; Fig. 8 A). These two populations can be readily
separated from one another by differential affinity to mag-
netic beads coated with LTR-specific mAb TCN-2 (32).
The subset that produces TS, named TS1, represents 25%
of the total trypomastigote population, whereas the subset
that does not produce or produces very little TS, termed
TS2, constitutes the majority of the trypomastigotes (32).
Interestingly, TS1 parasites of the Silvio strain are short and
stumpy (length 5 9.3 6 2.8 mm) and morphologically dis-
tinct from the TS2 parasites, which are slender (length 5
18.2  6  4.3  mm) (Fig. 8 C). Live TS1 trypomastigotes
moved slowly and sluggishly in liquid medium (10% FCS/
RPMI) at room temperature, contrary to the TS2 trypo-
mastigotes, which migrated swiftly with a whipping move-
ment (data not shown). However, the dimorphism and con-
trasting movements of TS1 and TS2 trypomastigotes were
not characteristic features of two other T. cruzi strains, Tu-
lahuen and MV-13 (data not shown). Thus, there does not
appear to be a relation between the expression of TS and a
particular morphological type of T. cruzi. It remains to be
determined why the TS1 and TS2 trypomastigotes of the
Silvio strain, but not of the other strains, are so morpholog-
ically distinguishable from one another.
Nevertheless, the availability of purified TS1 and TS2
populations offered a unique opportunity to test the power
Figure 6. Live trypomastigotes, but not epimastigotes, induce IL-6 se-
cretion in normal PBMCs. (A) The trans-sialidase activity of trypomasti-
gotes (Trypos) and epimastigotes (Epis). Live parasites (2 3 106 per reac-
tion) were added to the TS reaction mixture containing 1% nonionic
detergent to lyse the cells. Newly formed sialylated [14C]lactosamine was
determined after 4 h incubation at room temperature. (B) IL-6 secretion
after coculture of trypomastigotes with normal PBMCs. 106 PBMCs were
cocultured with 105 trypomastigotes or epimastigotes for 48 h, and IL-6
was determined in the cell-free supernatants at the indicated times.
Table I. Structure of Synthetic TR Peptides Modeled on the Proximal Sequence of the LTR from Silvio TS
Peptides Amino acid sequence
TR1 DSSAHGAPSTPA
TR2 DSSAHGAPSTPADSSAHGTPSTPV
TR3 DSSAHGAPSTPADSSAHGTPSTPVDSSAHGTPSTPA
TR4 DSSAHGAPSTPADSSAHGTPSTPVDSSAHGTPSTPADSSAHSTPSTPA
TR5 DSSAHGAPSTPADSSAHGTPSTPVDSSAHGTPSTPADSSAHSTPSTPADSSAHSTPSTPA
Note that the TR1 unit is faithfully reproduced in the other peptides except as indicated by underlining.1832 The Trypanosoma cruzi Neuraminidase Stimulates IL-6 Secretion
of live parasites with variable TS abundance to upregulate
IL-6 in normal human cells. Therefore, we challenged
HIMEC monolayers with live TS1 and TS2 parasites and
followed the time course of IL-6 released in the trypano-
some-containing culture supernatants. It was remarkable to
find that TS1 trypomastigotes were much more effective
than TS2, and somewhat better than unfractionated trypo-
mastigotes, in inducing intestinal endothelial cells to release
IL-6 (Fig. 8 B). The result in Fig. 8 B is for the subpopula-
tions of the Silvio strain, but similar results were obtained
with the TS1 and TS2 subsets of the Tulahuen strain (data
not shown). Because the TS1 parasites of the Tulahuen
strain are a mixture of stumpy and slender forms, the power
of T. cruzi to induce IL-6 secretion in naive human cells
depends on the TS content, rather than on the morphology
of the parasites. Furthermore, the inability of L. major pro-
mastigotes (which do not have TS activity [see Fig. 8 A]) to
release IL-6 in HIMECs (Fig. 8 B) suggests that parasite
burden per se does not suffice to induce IL-6 secretion in
naive human cells.
Discussion
Infection of mammals by parasites and other microbes
results in the release of cytokines and other mediators of the
inflammatory response. The composition of the cytokines,
which depends on the nature of the infecting organism and
on the host genotype, may be critical for the resistance or
susceptibility to microbial invasion, as best exemplified by
the infection of mice with the protozoan L. major (44) and
of humans with the bacterium Mycobacterium leprae (45).
It is generally accepted that cytokine networks result
from antigenic stimulation of lymphocytes and macrophages.
However, these antigen-driven host responses can be sub-
verted by a group of viral and bacterial proteins, termed vi-
rokines and bacteriokines, respectively, which are capable
of changing the dynamics of the cytokine networks with-
out directly activating B and T cell receptors (46). Viro-
kines tend to suppress host immune responses by neutraliz-
ing inflammatory cytokines, as is the case of the protein
B15R of vaccinia virus, which binds IL-1b (47). Alterna-
tively, virokines may downmodulate immune responses by
mimicking antiinflammatory cytokines, like the protein
BCRF1 of Epstein-Barr virus, which is 70% identical to IL-10
(48). On the other hand, bacteriokines, including LPS and
exotoxins, are more likely to stimulate proinflammatory cy-
tokines, thereby enhancing pathogenesis (46). Whether pro-
tozoan parasites can alter host immune responses through
molecules functionally equivalent to virokines and bacterio-
kines (i.e., “protokines”) remains to be determined.
The findings reported in this paper identify TS as a pro-
tein that could alter the dynamics of the cytokine network
by upregulating IL-6 secretion in normal human cells. As
shown in Figs. 1, 5, 7, and 8, TS and its TR were active
against naive microvascular endothelial cells and PBMCs.
Furthermore, given that IL-6 may be produced by many
other cell types, such as fibroblasts and epithelial cells, the
range of cell target for IL-6 release by TS could be broader
than the vascular endothelium and blood mononuclear
cells. This was indicated by the ability of TS to induce IL-6
release in the T-24 bladder carcinoma cells (Fig. 1) and by
parallel experiments with mouse cells, which revealed TS
to be an upregulator of IL-6 secretion in naive splenocytes,
bone marrow cells, and peritoneal cells from BALB/c and
other strains of mice (Gao, W., and M.A. Pereira, manu-
script in preparation). Therefore, TS upregulates IL-6 se-
cretion in various cell types and animal species.
The kinetics of TS-dependent IL-6 release in vitro (Fig. 1,
D and E, and Fig. 2) suggests that, in vivo, TS should stimu-
late IL-6 release before the full development of acquired im-
mune response against T. cruzi. This could be accomplished
when T. cruzi first encounters the mammalian host, such as
after an insect bite when the parasites enter the host through
the mucosa, usually around the eye; or when T. cruzi enters
the host during blood transfusion or congenitally, in which
case the TS1 parasites gain access into the circulation where
they should react with endothelial cells and PBMCs to trigger
IL-6 release. In addition, TS may also promote IL-6 secretion
in vivo as a soluble mediator. Indeed, soluble neuraminidase
was detected, before the parasites, in the blood of a T. cruzi–
infected individual (24). Copious amounts of the enzyme are
released in monolayers of cells infected with T. cruzi (20).
Our findings reported here show that soluble enzyme and
TS-expressing parasites are capable of inducing IL-6 secretion
in normal cells.
There are several ways in which TS-dependent IL-6
could alter T. cruzi invasion. IL-6 promotes polyclonal acti-
vation of B and T lymphocytes (49, 50) and is an important
cofactor for Th2 T cell activation, necessary for the induc-
tion of humoral immune responses (51). Thus, the TS/IL-6
pathway could be directly relevant to the polyclonal lym-
phocyte responses that characterize acute Chagas’s disease
(52). In addition, IL-6 is a potent inducer of collagen secre-
Figure 7. LTR-based synthetic peptides stimulate IL-6 release in PB-
MCs. Synthetic peptides, at the indicated concentrations, were added to
PBMCs for 24 h, and the conditioned supernatants were assayed for IL-6
by ELISA. TR1 refers to 1 repeat (12 amino acids), TR2 to 2 repeats, and
so on. For the sequence of the repeats, see Table I.1833 Saavedra et al.
tion in human fibroblasts (53), and as such appears to underlie
the pathogenesis of systemic sclerosis, a connective tissue
disease characterized by fibrosis in the skin and internal or-
gans (54). The fibrogenic action of IL-6 could also be rele-
vant to T. cruzi infection, as fibrosis is a prominent feature
of acute and chronic Chagas’s disease (55, 56). Because
chronic chagasic heart contains many IL-6–containing mono-
nuclear cells and endothelial cells (4–7), IL-6 could in theory
contribute to the fibrosis in the chronic heart, regardless of
the mechanism stimulating production of the cytokine.
IL-6, in addition to mediating inflammatory and immune
responses, may play an important role in a variety of activi-
ties of the central and peripheral nervous systems, such as cell-
to-cell signaling, protection of neurons from insult, and neu-
ronal growth and survival (57). Thus, TS-dependent IL-6
could be a factor in the neuroregeneration that character-
izes the indeterminate phase of Chagas’s disease in humans
(55) and animals (58). In support of this hypothesis, we re-
cently found TS to be extremely potent in protecting several
types of neuronal cells from undergoing apoptosis induced by
growth factor deprivation (Chuenkova, M., and M.A. Pereira,
manuscript submitted for publication). What’s more, the
TS-induced neuroprotection was synergistic with two mem-
bers of the IL-6 family, ciliary neurotrophic factor and leu-
kemia inhibitory factor (Chuenkova, M., and M.A. Pereira,
manuscript submitted for publication). Thus, the neuro-
trophic effect of TS-dependent IL-6 could be boosted by the
action of TS and by the TS synergy with ciliary neurotrophic
factor or leukemia inhibitory factor on the neurons.
TS itself has been implicated as a key factor in T. cruzi
invasion. Experiments with cells in culture suggest that TS
promotes parasite attachment to host cells through the
recognition of sialyl-containing surface receptors (59, 60).
Experiments in vivo are also consistent with TS being a
promoter of T. cruzi invasion, as suggested by the enhance-
ment of infection in experimental models of Chagas’s dis-
ease by LTR-specific polyclonal (61) and monoclonal (62,
24) antibodies, and by the inhibition of infection by CD-
specific antibodies (63, 64). In addition, antibodies against
TS-generated sialyl epitopes present on the trypomastigote
surface block infection as well (65). Finally, the enhance-
ment of T. cruzi virulence in BALB/c mice sensitized with
low doses of the enzyme further supports the conclusion
that TS is a major factor in promoting T. cruzi invasion of
mammalian hosts (25). The novel findings reported here
open up strategies to investigate an unsuspected role for TS
in T. cruzi invasion and provide a new tool to study the
function of IL-6 in Chagas’s disease.
Figure 8. Differential release of IL-6 by HIMECs
after infection with TS1 and TS2 trypomastigotes.
(A) The trans-sialidase activity of unfractionated try-
pomastigotes (Unf), trypomastigote populations with
phenotypes TS1 and TS2, and L. major promasti-
gotes. (B) IL-6 released by HIMECs after infection
with the indicated trypomastigote populations and L.
major promastigotes. (C) The morphology of TS2,
TS1, and unfractionated trypomastigotes of the Silvio
X-10/4 of T. cruzi stained with Diff-Quik. Original
magnification: 31,200.1834 The Trypanosoma cruzi Neuraminidase Stimulates IL-6 Secretion
We thank Drs. Claudio Fiocchi and Gail West for the generous gift of HIMECs and for advice, Marina
Chuenkova for the CD domain and for discussions, Edouard Vannier and Charles Dinarello for initial radio-
immunoassays to detect IL-1b and TNF-a in TS-conditioned supernatants of PBMCs, Thereza Imanishi-
Kari for the anti–p-azo-phenylarsonate mAb IgG1, and Daniel Eichinger for suggesting the use of the Y
strain constructs.
This work was supported by National Institutes of Health grant AI18102.
Address correspondence to Miercio A. Pereira, Department of Pathology, Parasitology Research Center,
Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111. Phone: 617-636-2933; Fax:
617-636-6849; E-mail: maperrin@yahoo.com
Submitted: 30 June 1999 Revised: 1 September 1999 Accepted: 30 September 1999
References
1. Tanowitz, H.B., J.P. Gumprecht, D. Spurr, T.M. Calderon,
M.C. Ventura, C. Raventos-Suarez, S. Kellie, S.M. Factor,
V.B. Hatcher, M. Wittner, and J.W. Berman. 1992. Cyto-
kine gene expression of endothelial cells infected with Trypa-
nosoma cruzi. J. Infect. Dis. 166:598–603.
2. Van Voorhis, W.C. 1992. Coculture of human peripheral
blood mononuclear cells with Trypanosoma cruzi leads to pro-
liferation of lymphocytes and cytokine production. J. Immu-
nol. 148:239–248.
3. Truyens, C., A. Angelo-Barrios, F. Torrico, J. van Damme,
H. Heremans, and Y. Carlier. 1994. Interleukin-6 (IL-6)
production in mice infected with Trypanosoma cruzi: effect of
its paradoxical increase by anti-IL-6 monoclonal antibody
treatment on infection and acute-phase and humoral immune
responses. Infect. Immun. 62:692–696.
4. Chandrasekar, B., P.C. Melby, D.A. Troyer, and G.L. Free-
man. 1996. Induction of proinflammatory cytokine expres-
sion in experimental acute chagasic cardiomyopathy. Biochem.
Biophys. Res. Commun. 223:365–371.
5. Sunnemark, D., A.-K. Ulfgren, A. Orn, and R.A. Harris.
1996. Cytokine production in hearts of Trypanosoma cruzi-
infected CBA mice: do cytokine patterns in chronic stage re-
flect the establishment of myocardial pathology? Scand. J. Im-
munol. 44:421–429.
6. Sunnemark, D., J. Frostegard, A. Orn, and R.A. Harris.
1998. Cellular and cytokine characterization of vascular in-
flammation in CBA/J mice infected with Trypanosoma cruzi.
Scand. J. Immunol. 48:480–484.
7. Zhang, L., and R. Tarleton. 1996. Persistent production of
inflammatory and anti-inflammatory cytokines and associated
MHC and adhesion molecule expression at the site of infec-
tion and disease in experimental Trypanosoma cruzi infections.
Exp. Parasitol. 84:203–213.
8. Glienke, W., R. Esser, H. von Briessen, K. Schuster, S. Muller,
R. Unger, R. Andreesen, H.J. Stutte, and H. Rubsamen-Waig-
man. 1994. Cytokine expression of HIV-infected monocytes/
macrophages at the single-cell level. Res. Virol. 145:193–197.
9. Breen, E.C., A.R. Rezai, K. Nakajima, G.N. Beall, R.T.
Mitsuyasu, T. Hirano, T. Kishimoto, and O. Martinez-Maza.
1990. Infection with HIV is associated with elevated IL-6
levels and production. J. Immunol. 144:480–484.
10. Rieckmann, P., G. Poli, J.H. Kehlr, and A.S. Fauci. 1991.
Activated B lymphocytes from human immunodeficiency vi-
rus–infected individuals induce virus expression in infected T
cells and a promonocytic cell line, U1. J. Exp. Med. 173:1–5.
11. Ambrosino, C., M.R. Ruocco, X. Chen, M. Mallardo, F.
Baudi, S. Trematerra, I. Quinto, S. Venuta, and G. Scala.
1997. HIV-1 Tat induces the expression of the interleukin-6
(IL-6) gene by binding to the IL-6 leader RNA and by inter-
acting with CAAT enhancer-binding protein beta (NF-IL6)
transcription factors. J. Biol. Chem. 272:14883–14892.
12. Gong, J.-H., H. Sprenger, F. Hinder, A. Bender, A. Schmidt,
S. Horch, M. Nain, and D. Gemsa. 1991. Influenza A virus
infection of macrophages. Enhanced tumor necrosis factor-a
(TNF-a) gene expression and lipopolysaccharide-triggered
TNF-a release. J. Immunol. 147:3507–3513.
13. Hayden, F.G., R.S. Fritz, M.C. Lobo, W.G. Alvord, W.
Strober, and S.E. Straus. 1998. Local and systemic cytokine
responses during experimental human influenza A virus in-
fection. J. Clin. Invest. 101:643–649.
14. Zhu, Z., W. Tang, A. Ray, Y. Wu, O. Einarsson, M.L. Lan-
dry, J. Gwaltney, Jr., and J.A. Elias. 1996. Rhinovirus stimu-
lation of interleukin-6 in vivo and in vitro. J. Clin. Invest. 97:
421–430.
15. Sher, A., and R.L. Coffman. 1992. Regulation of immunity
to parasites by T cells and T cell-derived cytokines. Annu.
Rev. Immunol. 10:385–409.
16. DosReis, G.A. 1997. Cell-mediated immunity in experimen-
tal Trypanosoma cruzi infection. Parasitol. Today. 13:335–342.
17. Pereira, M.E.A. 1983. A developmentally regulated neuramini-
dase activity in Trypanosoma cruzi. Science. 219:1444–1447.
18. Schenkman, S.L., P. de Carvalho, and V. Nussenzweig.
1992.  Trypanosoma cruzi trans-sialidase and neuraminidase ac-
tivities can be mediated by the same enzyme. J. Exp. Med.
175:567–575.
19. Parodi, A.J., G.D. Pollevick, M. Mautner, A. Buschiazzo,
D.O. Sanchez, and A.C.C. Frasch. 1992. Identification of the
gene(s) coding for the trans-sialidase of Trypanosoma cruzi.
EMBO (Eur. Mol. Biol. Organ.) J. 11:1705–1710.
20. Scudder, P., J.P. Doom, M. Chuenkova, I.D. Manger, and
M.E.A. Pereira. 1993. Enzymatic characterization of the
b-d-galactoside a2,3-trans-sialidase from Trypanosoma cruzi.
J. Biol. Chem. 268:9886–9891.
21. Schenkman, S., D. Eichinger, M.E.A. Pereira, and V. Nus-
senzweig. 1994. Structural and functional properties of trypa-
nosoma trans-sialidase. Annu. Rev. Microbiol. 48:499–532.
22. Pereira, M.E.A., J.S. Mejia, E. Ortega-Barria, D. Matzilevich,
and R.P. Prioli. 1991. The Trypanosoma cruzi neuraminidase
contains sequences similar to bacterial neuraminidases, YWTD
repeats of the low-density lipoprotein receptor, and type III1835 Saavedra et al.
modules of fibronectin. J. Exp. Med. 174:179–191.
23. Rosenberg, I., R.P. Prioli, E. Ortega-Barria, and M.E.A.
Pereira. 1991. Stage-specific phospholipase C mediated re-
lease of Trypanosoma cruzi neuraminidase. Mol. Biochem. Para-
sitol. 46:303–306.
24. De Titto, E., and F.G. Araujo. 1988. Serum neuraminidase
activity and hematological alterations in acute human Chagas’
disease. Clin. Immunol. Immunopathol. 46:157–161.
25. Chuenkova, M., and M.E.A. Pereira. 1995. Trypanosoma
cruzi trans-sialidase: enhancement of virulence in a murine
model of Chagas’ disease. J. Exp. Med. 181:1693–1703.
26. Strong, S.A., T.T. Pizarro, J.S. Klein, F. Cominelli, and C.
Fiocchi. 1998. Proinflammatory cytokines differentially mod-
ulate their own expression in human intestinal mucosal mes-
enchymal cells. Gastroenterology. 114:1244–1256.
27. Coligan, J.E., A.M. Kruisbeek, D.H. Margulies, E.M. She-
vach, and W. Strober. 1995. Current Protocols in Immunol-
ogy. John Wiley & Sons, Inc., New York. 7.1.1–7.1.2.
28. Ortega-Barria, E., and M.E.A. Pereira. 1991. A novel T.
cruzi heparin-binding protein promotes fibroblast adhesion
and penetration of engineered bacteria and trypanosomes
into mammalian cells. Cell. 67:411–421.
29. Uemura, H., S. Schenkman, V. Nussenzweig, and D. Eich-
inger. 1992. Only some members of a gene family of Trypa-
nosoma cruzi encode proteins that express both trans-sialidase
and neuraminidase activities. EMBO (Eur. Mol. Biol. Organ.)
J. 11:3837–3844.
30. Bock, G.H., C.A. Long, M.L. Riley, J.D. White, C.C. Kur-
man, T.A. Fleischer, M. Tsokos, M. Brown, D. Serbousek,
and W.D. Schwietermann. 1993. Characterization of a new
IL-6 dependent human B-lymphoma cell line in long term
culture. Cytokine. 5:480–489.
31. Wong, H., W.D. Anderson, T. Cheng, and K.T. Riabowo.
1994. Monitoring mRNA expression by polymerase chain
reaction: the “primer-dropping” method. Anal. Biochem. 223:
251–258.
32. Pereira, M.E.A., K. Zhang, Y. Gong, E.M. Herrera, and M.
Ming. 1996. Invasive phenotype of Trypanosoma cruzi re-
stricted to a population expressing trans-sialidase. Infect. Im-
mun. 64:3884–3892.
33. Swerlick, R.A., and T.J. Lawley. 1993. Role of microvascu-
lar endothelial cells in inflammation. J. Invest. Dermatol. 100:
111S–115S.
34. Granger, D.N., and P. Kubes. 1994. The microcirculation
and inflammation: modulation of leukocyte-endothelial cell
adhesion. J. Leukoc. Biol. 55:662–675.
35. Augustin, H.G., D.T. Kozian, and R.C. Johnson. 1994. Dif-
ferentiation of endothelial cells: analysis of the constitutive and
activated endothelial cell phenotypes. Bioessays. 16: 901–906.
36. Binion, D.G., G.A. West, K. Ina, N.P. Ziats, S.N. Emanci-
pator, and C. Fiocchi. 1997. Enhanced leukocyte binding by
intestinal microvascular endothelial cells in inflammatory
bowel disease. Gastroenterology. 112:1895–1907.
37. Nilsen, E.M., F.-E. Johansen, F.L. Jahnsen, K.E.A. Lundin,
T. Scholz, P. Brandtzaeg, and G. Haraldsen. 1998. Cytokine
profiles of cultured microvascular endothelial cells from hu-
man intestine. Gut. 42:635–642.
38. Bubenik, J., M. Baresova, V. Viklicky, J. Jakoubkova, H.
Sainerova, and J. Donner. 1973. Established cell line of uri-
nary bladder carcinoma (T24) containing tumor-specific an-
tigen. Int. J. Cancer. 11:765–773.
39. Yasukawa, K., T. Hirano, Y. Watanabe, K. Muratani, T.
Matsuda, S. Nakai, and T. Kishimoto. 1987. Structure and
expression of human B cell stimulatory factor-2 (BSF-2/IL-
6) gene. EMBO (Eur. Mol. Biol. Organ.) J. 6:2939–2945.
40. Stein, B., and M.S.K. Sutherland. 1998. IL-6 as a drug dis-
covery target. Drug Discovery Today. 3:202–213.
41. Cicco, N.A., A. Lindemann, J. Content, P. Vandenbussche,
M. Lubbert, J. Gauss, R. Mertelsmann, and F. Herrmann.
1990. Inducible production of interleukin-6 by human poly-
morphonuclear neutrophils: role of granulocyte-macrophage
colony stimulating factor and tumor necrosis factor-alpha.
Blood. 75:2049–2052.
42. Chaves, L.B., M.R. Briones, and S. Schenkman. 1993.
Trans-sialidase from Trypanosoma cruzi epimastigotes is ex-
pressed at the stationary phase and is different from the en-
zyme expressed in trypomastigotes. Mol. Biochem. Parasitol.
61:97–106.
43. Briones, M.R., C.M. Egima, and S. Schenkman. 1995. Try-
panosoma cruzi trans-sialidase gene lacking C-terminal repeats
and expressed in epimastigote forms. Mol. Biochem. Parasitol.
70:9–17.
44. Reiner, S.L., and R.M. Locksley. 1995. The regulation of
immunity to Leishmania major. Annu. Rev. Immunol. 13:
151–177.
45. Yamamura, M., X.H. Wang, J.D. Ohmen, K. Uyemura,
T.H. Rea, B.R. Bloom, and R.L. Modlin. 1992. Cytokine
patterns of immunologically mediated tissue damage. J. Im-
munol. 149:1470–1475.
46. Wilson, M., R. Seymour, and B. Henderson. 1998. Bacterial
perturbation of cytokine networks. Infect. Immun. 66:2401–
2409.
47. Alcami, A., and G.L. Smith. 1992. A soluble receptor for in-
terleukin–1 beta encoded by vaccinia virus: a novel mecha-
nism of virus modulation of the host response to infection.
Cell. 71:153–167.
48. Hsu, D.H., R. de Waal-Malfyt, D.F. Fiorentino, M.-N.
Dang, P. Vieira, J. deVries, H. Spits, T.R. Mosmann, and
K.W. Moore. 1990. Expression of interleukin-10 activity by
Epstein-Barr virus protein BCRF1. Science. 250:830–832.
49. Kishimoto, T. 1989. The biology of interleukin-6. Blood. 74:
1–10.
50. Uyttenhove, C., P.G. Coulie, and J. Van Snick. 1988. T cell
growth and differentiation induced by interleukin-HP1/IL-
6, the murine hybridoma/plasmacytoma growth factor. J.
Exp. Med. 167:1417–1427.
51. Rincon, M., J. Anguita, T. Nakamura, E. Fikrig, and R.A.
Flavell. 1997. Interleukin (IL)-6 directs the differentiation of
IL-4–producing CD41 T cells. J. Exp. Med. 185:461–469.
52. Minoprio, P.M., H. Eisen, L. Forni, M.R. D’Imperio Lima,
M. Joskowicz, and A. Coutinho. 1986. Polyclonal lympho-
cyte responses to murine Trypanosoma cruzi infection. I.
Quantitation of both T- and B-cell responses. Scand. J. Immu-
nol. 24:661–668.
53. Duncan, M.R., and B. Berman. 1991. Stimulation of col-
lagen and glycosaminoglycan production in cultured human
adult dermal fibroblasts by recombinant human interleukin 6.
J. Invest. Dermatol. 97:686–692.
54. Kawaguchi, Y., M. Hara, and T.M. Wright. 1999. Endoge-
nous IL-1a from systemic sclerosis fibroblasts induces IL-6
and PDGF-A. J. Clin. Invest. 103:1253–1260.
55. Kÿberle, F. 1974. Pathogenesis of Chagas’ disease. Ciba
Found. Symp. 20:137–147.
56. Andrade, Z.A. 1983. Mechanisms of myocardial damage in
Trypanosoma cruzi infection. Ciba Found. Symp. 99:214–233.
57. Gruol, D.L., and T.E. Nelson. 1997. Physiological and1836 The Trypanosoma cruzi Neuraminidase Stimulates IL-6 Secretion
pathological roles of interleukin-6 in the central nervous sys-
tem. Mol. Neurobiol. 15:307–339.
58. Tafuri, W.L. 1970. Pathogenesis of lesions of the autonomic
nervous system of the mouse in experimental acute Chagas’
disease. Am. J. Trop. Med. Hyg. 19:405–417.
59. Ming, M., M. Chuenkova, E. Ortega-Barria, and M.E.A.
Pereira. 1993. Mediation of Trypanosoma cruzi invasion by
sialic acid on the host cell and trans-sialidase on the trypano-
somes. Mol. Biochem. Parasitol. 59:243–252.
60. Schenkman, R.P., F. Vandekerckhove, and S. Schenkman.
1993. Mammalian cell sialic acid enhances Trypanosoma cruzi
invasion. Infect. Immun. 61:898–902.
61. Cavalesco, R., and M.E.A Pereira. 1988. Antibody to Trypa-
nosoma cruzi neuraminidase enhances infection in vitro and
identifies a subpopulation of trypomastigotes. J. Immunol.
140:617–625.
62. Prioli, R.P., J.S. Mejia, and M.E.A. Pereira. 1990. Mono-
clonal antibodies against Trypanosoma cruzi neuraminidase re-
veal enzyme polymorphism, recognize a subset of trypomas-
tigotes, and enhance infection in vitro. J. Immunol. 144:4384–
4389.
63. Costa, F., G. Franchin, V.L. Pereira-Chioccola, M. Riberao,
S. Schenkman, and M.M. Rodrigues. 1998. Immunization
with a plasmid DNA containing the gene of trans-sialidase re-
duces Trypanosoma cruzi infection in mice. Vaccine. 16:768–774.
64. Leguizamon, M.S., O.E. Campetella, S.M. Gonzalez Cappa,
and A.C.C. Frasch. 1994. Mice infected with Trypanosoma cruzi
produce antibodies against the enzymatic domain of trans-siali-
dase that inhibit its activity. Infect. Immun. 62:3441–3446.
65. Franchin, G., V.L. Pereira-Chioccola, S. Schenkman, and
M.M. Rodrigues. 1997. Passive transfer of a monoclonal an-
tibody specific for a sialic acid-dependent epitope on the sur-
face of Trypanosoma cruzi trypomastigotes reduces infection in
mice. Infect. Immun. 65:2548–2554.